Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

15.65 -1.08 (-6.43%)
Streaming Delayed Price Updated: 12:40 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 Next >
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Enhances Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.